Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is exhibiting promising results in initial clinical studies. Current research https://getsocialsource.com/story6839145/retatrutide-emerging-investigations-and-possible-clinical-roles